Miralax and Relistor drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Miralax (polyethylene glycol 3350) and Relistor (methylnaltrexone bromide). Common drug interactions include dysphagia among females and weight decreased among males.

The phase IV clinical study analyzes what interactions people have when they take Miralax and Relistor. It is created by eHealthMe based on reports of 95 people who take the same drugs from the FDA, and is updated regularly.

What is Miralax?

Miralax has active ingredients of polyethylene glycol 3350. It is often used in constipation. eHealthMe is studying from 81,754 Miralax users. Check the latest studies of Miralax.

What is Relistor?

Relistor has active ingredients of methylnaltrexone bromide. eHealthMe is studying from 1,659 Relistor users. Check the latest studies of Relistor.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

95 people who take Miralax and Relistor together, and have interactions are studied.

What are the common drug interactions of Miralax and Relistor, by gender? *:

female:

Dysphagia (a condition in which swallowing is difficult or painful)
Infection
Oropharyngeal pain
Arthralgia (joint pain)
Confusional state
Dyspepsia (indigestion)
Dyspnoea (difficult or laboured respiration)
Herpes zoster
Oesophagitis (inflammation of oesophagus)
Acetabulum fracture (socket of the hip joint- fracture)

male:

Weight decreased
Nausea (feeling of having an urge to vomit)
Urinary tract infection
Alanine aminotransferase increased
Aspartate aminotransferase increased
Dry skin
Erythema (redness of the skin)
Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
Pneumonia

What are the common drug interactions of Miralax and Relistor, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Abdominal pain
Activities of daily living impaired
Anxiety
Clonus (series of involuntary, rhythmic, muscular contractions and relaxations)
Decubitus ulcer (a chronic ulcer of the skin caused by prolonged pressure on it)
Fall
Femur fracture
Hypertonia (abnormal increase in muscle tension and a reduced ability of a muscle to stretch)
Muscle spasticity (tight or stiff muscles and an inability to control those muscles)
Nausea (feeling of having an urge to vomit)

20-29:

Abdominal discomfort
Abdominal distension
Agitation (state of anxiety or nervous excitement)
Decubitus ulcer (a chronic ulcer of the skin caused by prolonged pressure on it)
Discomfort
Drug withdrawal syndrome (interfere with normal social, occupational, or other functioning. are not due to another medical condition, drug use, or discontinuation)
Fatigue (feeling of tiredness)
Gait disturbance
Hyperhidrosis (abnormally increased sweating)
Implant site infection

30-39:

Angina pectoris (chest pain due to ischemia of the heart muscle)
Arthritis (form of joint disorder that involves inflammation of one or more joints)
Hepatic enzyme increased
Narcolepsy (brain's inability to regulate sleep-wake cycles normally)
Oedema peripheral (superficial swelling)
Cellulitis (infection under the skin)
Immune thrombocytopenic purpura (destruction of blood platelets due to the presence of antiplatelet auto antibodies)
Staphylococcal abscess (pus formation due to staphylococcal bacteria)
Injection site haemorrhage (bleeding from injection site)
Disease progression

40-49:

Hypotension (abnormally low blood pressure)
Intestinal perforation (complete penetration of the wall of the intestine)
Nausea (feeling of having an urge to vomit)
Sepsis (a severe blood infection that can lead to organ failure and death)
Tachycardia (a heart rate that exceeds the range of 100 beats/min)
Vomiting
Abdominal pain upper
Diarrhoea
Dizziness
Drug ineffective

50-59:

Anxiety
Back pain
Bone lesion (bone with abnormalities. bone lesions can result from growth formations, infections, or injuries)
Bone pain
Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
Bursitis (inflammation of a bursa, typically one in the knee, elbow, or shoulder)
Cardiomyopathy (weakening of the heart muscle)
Cataract (clouding of the lens inside the eye)
Chest pain
Chills (felling of cold)

60+:

Weight decreased
Insomnia (sleeplessness)
Alanine aminotransferase increased
Anxiety
Aspartate aminotransferase increased
Back pain
Dry skin
Erythema (redness of the skin)
Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)

What are the existing conditions these people have? *

Pain: 25 people, 26.32%
Nausea (feeling of having an urge to vomit): 17 people, 17.89%
Stress And Anxiety: 11 people, 11.58%
Breast Cancer: 9 people, 9.47%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 8 people, 8.42%
Muscle Spasms (muscle contraction): 7 people, 7.37%
Neuropathy Peripheral (surface nerve damage): 6 people, 6.32%
Migraine (headache): 6 people, 6.32%
Sleep Disorder: 5 people, 5.26%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 5 people, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Miralax and Relistor?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously